Clinical trial

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of…

NCT00360035 · Gemin X, Industry · Completed

Key facts

NCT number NCT00360035
Title Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia
Official title A Multi-Center, Open-Label, Phase II Study of Single-Agent GX15-070MS Administered as a 24-Hour Infusion Every 2 Weeks to Patients With Myelofibrosis With Myeloid Metaplasia (MF)
Lead sponsor Gemin X, Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions Myelofibrosis
Intervention type Drug
Interventions Obatoclax mesylate (GX15-070MS)
Enrollment 22
Start date Jul 1, 2006
Primary completion Mar 1, 2008
Completion Feb 1, 2009
First posted Aug 3, 2006
Last update posted Aug 26, 2013
Countries Canada, United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies